T. Rawson

发表

Benzodiazepine peptidomimetic inhibitors of farnesyltransferase.

K. Chan, R. Mcdowell, M. Stanley, 1994, Bioorganic & medicinal chemistry.

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

A. Levinson, M. Brown, J. Goldstein, 1993, Science.

Synthesis of 3-Amino-l-CarboxymethyI-Benzodiazepine (BZA) Peptidomimetics.

J. Marsters, T. Rawson, 1999, Methods in molecular medicine.

Stereochemistry of the benzodiazepine based Ras farnesyltransferase inhibitors

J. Marsters, M. Reynolds, T. Somers, 1995 .

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.

Jane R Kenny, Michael Siu, Deepak Sampath, 2012, Journal of medicinal chemistry.

Abstract A20: Development and validation of a novel acute myeloid leukemia xenograft model that is dependent on the JAK2V617F mutation for growth in vivo

Leslie B. Lee, Christine Chang, D. Sampath, 2009 .

A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Jennafer Dotson, Christian Wiesmann, Jason Drummond, 2009, Journal of medicinal chemistry.

Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists.

I. Aliagas, R. Webb, T. Somers, 1998, Bioorganic & medicinal chemistry.

In vitro characterization of four novel classes of growth hormone-releasing peptide.

R. Mcdowell, M. Cronin, M. Stanley, 1995, Endocrinology.

The synthesis of a phorbol 12,13-bis-lactone

T. Rawson, T. Kogan, 1992 .

Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

K. Chan, W. Fairbrother, R. Clark, 1995, Proceedings of the National Academy of Sciences of the United States of America.

From Peptide to Non-Peptide. Part 2. The de novo Design of Potent, Non- Peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold.

Mark Reynolds, M. Venuti, E. Thorsett, 1994 .

A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo*

D. Banner, M. Ultsch, D. Sutherlin, 2005, Journal of Biological Chemistry.

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.

Guy Georges, Elizabeth Blackwood, Christian Wiesmann, 2008, Journal of medicinal chemistry.

From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold

Thomas Rawson, E. Thorsett, T. Gadek, 1994 .

The synthesis of chiral 3-oxo-6-[(phenylmethoxy)-carbonyl]-2-piperazineacetic acid esters designed for the presentation of an aspartic acid side chain. A subsequent novel Friedel Crafts reaction

T. Rawson, T. Kogan, 1992 .

Synthesis of N-Methylene-N,N-Bis(2-Chloroethyl) Ammonium Hexachlorostannate

T. Rawson, G. Pettit, 1981 .

Separation of 21-(R)- and 21-(S)-argatroban: solubility and activity of the individual diastereoisomers.

T. Rawson, T. Kogan, J. Yang, 1993, Journal of pharmaceutical sciences.

The Synthesis of 5′-Homo-2′-deoxycytidine

T. Webb, T. Rawson, 1990 .

Stability of the 1,4-bis(2′-haloethyl)-1,4-diazabicyclo[2.2.1]heptane dication

T. Rawson, G. Pettit, D. P. Gieschen, 1981 .

Potent α4β1 Peptide Antagonists as Potential Anti-Inflammatory Agents

Dean R. Artis, W. Fairbrother, Susan Jones, 1997 .

Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.

K. Chan, W. Fairbrother, D. R. Artis, 1997, Journal of medicinal chemistry.